ANI Pharmaceuticals has signed definitive agreements to acquire a portfolio of generic products and other assets from Amneal Pharmaceuticals and Impax Laboratories for an undisclosed cash consideration. The parties expect to close the transaction in early May.   Upon closing the transaction, ANI will acquire a product portfolio consisting of five approved generic ANDAs and one pipeline product, Erythromycin IR tablets. ANI will also acquire a license, supply and distribution agreement fo...